Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
克拉斯
医学
内科学
肿瘤科
癌症
结直肠癌
作者
Maximilian J. Hochmair,Karim Vermaelen,Giannis Mountzios,Enric Carcereny,Christophe Dooms,Se‐Hoon Lee,Éva Morócz,Terufumi Kato,Tudor–Eliade Ciuleanu,Grace K. Dy,Bárbara Parente,Kenneth V. Honn,Quincy Chu,Gilberto de Castro,Nicolas Girard,Wendy Snyder,Qui Tran,William Kormany,Brett E. Houk,Bhakti Mehta,Alessandra Curioni‐Fontecedro
Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg.
爱静静
嘉心糖
杳鸢
Billy
模糊中正
Jarvis Lin
YifanWang
tuanheqi
pcr163
Marciu33
年轻新晴
子车茗
andrele
自由一一
大模型
野性的柠檬
嗯哼
jyy
海风
0905
皖公网安备34019202002308
